• FDA Grants Fast Track Status to Investigational Compound CLR 131 for DLBCL
  • We Can Change Back
  • Dosing Begins in Study of TP-0903, With or Without Imbruvica, for Advanced CLL and SLL
  • TG Therapeutics to Seek Accelerated Approval of Umbralisib for Marginal Zone Lymphoma
  • REGN1979 Eliminated Cancer in Most Non-Hodgkin’s Lymphoma Patients in Phase 1 Trial
  • CHMP Recommends Expanding Imbruvica Use in the EU to Include 2 New Cancer Regimens
  • X4 Pharmaceuticals, LLS Collaborate to Develop Mavorixafor to Treat Waldenström’s Macroglobulinemia
  • Copiktra Induces Promising Clinical Activity in PTCL Patients, Phase 1 Trials Show
  • Zanubrutinib-Gazyva Shows Promise for CLL/SLL, Follicular Lymphoma
  • Pixuvri Gets Full Approval in Europe for Aggressive Non-Hodgkin’s B-cell Lymphomas, Servier Announced
  • Aliqopa Granted FDA’s Breakthrough Therapy Status for Previously Treated Marginal Zone Lymphoma
  • Forty Seven, Acerta Collaborate to Test Triple Combo Therapy on DLBCL Patients